Eduardo J. Contijoch

Eduardo J. Contijoch

Auto-generated profile, based on publicly available information

Eduardo J. Contijoch

Icahn School of Medicine at Mount Sinai

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Immunity
Verified
Journal Article
Closed access
GBGraham Britton
Graham Britton
ECEduardo J. Contijoch
Eduardo J. Contijoch
IMIlaria Mogno
Ilaria Mogno
OVOlivia H. Vennaro
Olivia H. Vennaro
SLSean R. Llewellyn
Sean R. Llewellyn
JFJeremiah J. Faith
Jeremiah J. Faith

9 July 2014 in Nature
Verified
Journal Article
Open access
PDF file
NSNetanya G. Sandler
Netanya G. Sandler
SBSteven E. Bosinger
Steven E. Bosinger
JEJacob D. Estes
Jacob D. Estes
RZRichard T. R. Zhu
Richard T. R. Zhu
GTGregory K. Tharp
Gregory K. Tharp
DDDaniel C. Douek
Daniel C. Douek
The timing of type I interferon signalling determines the disease course of SIV infection. Type I interferon (IFN-I) is shown here to have dual effects in rhesus macaques exposed to simian immunodeficiency virus (SIV): it is beneficial at the onset of infection but as infection progresses it becomes detrimental. IFN signaling was manipulated in two ways. IFN-I receptor blockade results in increased plasma viraemia, accelerated CD4 T cell loss and progression to AIDS. In contrast, IFN-α2a administration prior to high-dose intrarectal SIV challenge increases resistance to systemic infection. However, continued IFN-α2a treatment induces IFN-I desensitization and facilitates SIV infection. Overall, the benefits of early antiviral activity appear to outweigh the detrimental effects of immune activation during acute SIV infection. Inflammation in HIV infection is predictive of non-AIDS morbidity and death1, higher set point plasma virus load2 and virus acquisition3; thus, therapeutic agents are in development to reduce its causes and consequences. However, inflammation may simultaneously confer both detrimental and beneficial effects. This dichotomy is particularly applicable to type I interferons (IFN-I) which, while contributing to innate control of infection4,5,6,7,8,9,10, also provide target cells for the virus during acute infection, impair CD4 T-cell recovery, and are associated with disease progression6,7,11,12,13,14,15,16,17,18,19. Here we manipulated IFN-I signalling in rhesus macaques (Macaca mulatta) during simian immunodeficiency virus (SIV) transmission and acute infection with two complementary in vivo interventions. We show that blockade of the IFN-I receptor caused reduced antiviral gene expression, increased SIV reservoir size and accelerated CD4 T-cell depletion with progression to AIDS despite decreased T-cell activation. In contrast, IFN-α2a administration initially upregulated expression of antiviral genes and prevented systemic infection. However, continued IFN-α2a treatment induced IFN-I desensitization and decreased antiviral gene expression, enabling infection with increased SIV reservoir size and accelerated CD4 T-cell loss. Thus, the timing of IFN-induced innate responses in acute SIV infection profoundly affects overall disease course and outweighs the detrimental consequences of increased immune activation. Yet, the clinical consequences of manipulation of IFN signalling are difficult to predict in vivo and therapeutic interventions in human studies should be approached with caution.

1 March 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SLSean R. Llewellyn
Sean R. Llewellyn
GBGraham Britton
Graham Britton
ECEduardo J. Contijoch
Eduardo J. Contijoch
OVOlivia H. Vennaro
Olivia H. Vennaro
AMArthur Mortha
Arthur Mortha
JFJeremiah J. Faith
Jeremiah J. Faith

18 February 2020 in Cell Host & Microbe
Verified
Journal Article
Closed access
CYChao Yang
Chao Yang
IMIlaria Mogno
Ilaria Mogno
ECEduardo J. Contijoch
Eduardo J. Contijoch
JBJoshua N. Borgerding
Joshua N. Borgerding
VAVarun Aggarwala
Varun Aggarwala
JFJeremiah J. Faith
Jeremiah J. Faith

22 January 2019 in eLife
Verified
Journal Article
Open access
ECEduardo J Contijoch
Eduardo J Contijoch
GBGraham Britton
Graham Britton
CYChao Yang
Chao Yang
IMIlaria Mogno
Ilaria Mogno
ZLZhihua Li
Zhihua Li
JFJeremiah J Faith
Jeremiah J Faith
To identify factors that regulate gut microbiota density and the impact of varied microbiota density on health, we assayed this fundamental ecosystem property in fecal samples across mammals, human disease, and therapeutic interventions. Physiologic features of the host (carrying capacity) and the fitness of the gut microbiota shape microbiota density. Therapeutic manipulation of microbiota density in mice altered host metabolic and immune homeostasis. In humans, gut microbiota density was reduced in Crohn’s disease, ulcerative colitis, and ileal pouch-anal anastomosis. The gut microbiota in recurrent Clostridium difficile infection had lower density and reduced fitness that were restored by fecal microbiota transplantation. Understanding the interplay between microbiota and disease in terms of microbiota density, host carrying capacity, and microbiota fitness provide new insights into microbiome structure and microbiome targeted therapeutics.

18 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
GBGraham Britton
Graham Britton
ECEduardo J. Contijoch
Eduardo J. Contijoch
MSMatthew P. Spindler
Matthew P. Spindler
VAVarun Aggarwala
Varun Aggarwala
BDBelgin Dogan
Belgin Dogan
JFJeremiah J. Faith
Jeremiah J. Faith
The building evidence for the contribution of microbiota to human disease has spurred an effort to develop therapies that target the gut microbiota. This is particularly evident in inflammatory bowel diseases (IBDs), where clinical trials of fecal microbiota transplantation have shown some efficacy. To aid the development of novel microbiota-targeted therapies and to better understand the biology underpinning such treatments, we have used gnotobiotic mice to model microbiota manipulations in the context of microbiotas from humans with inflammatory bowel disease. Mice colonized with IBD donor-derived microbiotas exhibit a stereotypical set of phenotypes, characterized by abundant mucosal Th17 cells, a deficit in the tolerogenic RORγt+ regulatory T (Treg) cell subset, and susceptibility to disease in colitis models. Transplanting healthy donor-derived microbiotas into mice colonized with human IBD microbiotas led to induction of RORγt+ Treg cells, which was associated with an increase in the density of the microbiotas following transplant. Microbiota transplant reduced gut Th17 cells in mice colonized with a microbiota from a donor with Crohn’s disease. By culturing strains from this microbiota and screening them in vivo, we identified a specific strain that potently induces Th17 cells. Microbiota transplants reduced the relative abundance of this strain in the gut microbiota, which was correlated with a reduction in Th17 cells and protection from colitis. Significance Composition of gut microbiota is altered in many human diseases, including inflammatory bowel disease. Some hope that restoring microbiota to a healthy state could help treat such diseases. We have used mice colonized with microbiotas from humans with inflammatory bowel disease to study what happens when these mice receive a microbiota transplant from a set of healthy humans. We find that the mouse gut immune system is changed by microbiota transplants, becoming broadly less inflammatory and protecting mice from colitis. By culturing bacteria from these microbiotas, we identify one strain that induces inflammatory responses in mice and show that it is modified by microbiota transplant. We also show that increases in the density of microbiota following transplant may be antiinflammatory.